バイオ医薬品CMOおよびCROの世界市場レポート 2025年

バイオ医薬品CMO（医薬品製造受託機関）およびCRO（医薬品開発受託機関）市場は、研究開発への投資の増加により成長が見込まれています。こうした投資の背景には、技術革新の必要性、競合からのプレッシャー、市場の需要の変化、政府のインセンティブといった要因があります。研究開発資金の強化により、CMOとCROは改善された製造技術と調査方法を開発し、その能力と効率を高めることができます。このようにイノベーションに注力することで、規制遵守を確保しながら先進的なソリューションを提供し、顧客を惹きつけ、維持することができます。例えば、ユーロスタットが2023年12月に発表したところによると、EUの研究開発費は2022年に3,520億ユーロ（3,844億2,000万米ドル）に達し、前年の3,310億ユーロ（3,614億8,000万米ドル）から6.34%増加しました。この研究開発投資の拡大が、バイオ医薬品CMOおよびCRO市場の拡大に拍車をかけています。

バイオ医薬品CMOおよびCRO市場の主要企業は、バイオ医薬品企業のサービス向上、効率化、医薬品市場開拓のスピードアップを図るため、戦略的パートナーシップを結んでいます。戦略的パートナーシップとは、企業がそれぞれの強みとリソースを組み合わせ、共通の目標と相互の成功を達成することです。例えば、2024年6月、英国を拠点とするバイオ医薬品会社アブゼナは、米国を拠点とする医薬品開発・製造受託機関（CMO）であるアルゴノート・マニュファクチャリング・サービス社と提携し、統合的な医薬品開発・製造ソリューションを提供することになりました。この提携は、より迅速でエンド・ツー・エンドの医薬品開発・製造プロセスを実現し、効率性の向上、コスト削減、バイオ医薬品製造の合理化を顧客に提供することを目的としています。

2024年6月、米国を拠点とする投資会社グレート・ポイント・パートナーズは、リョーコントラクト社を非公開の金額で買収しました。この買収により、グレート・ポイント・パートナーズは、無菌液体充填、凍結乾燥、注射薬包装を含むリオコントラクト社の受託製造能力を強化することができます。ドイツに本社を置くLyocontract GmbHは、医薬品の受託開発・製造を専門とするCDMOです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界バイオ医薬品CMOおよびCRO PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のバイオ医薬品CMOおよびCRO市場：成長率分析
• 世界のバイオ医薬品CMOおよびCRO市場の実績：規模と成長, 2019-2024
• 世界のバイオ医薬品CMOおよびCRO市場の予測：規模と成長, 2024-2029, 2034F
• 世界バイオ医薬品CMOおよびCRO総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のバイオ医薬品CMOおよびCRO市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生物学的製剤
• バイオシミラー
• 世界のバイオ医薬品CMOおよびCRO市場：サービスタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 契約製造
• 契約調査
• 世界のバイオ医薬品CMOおよびCRO市場：ソース別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 哺乳類
• 非哺乳類
• 世界のバイオ医薬品CMOおよびCRO市場、生物製剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体（mAbs）
• ワクチン
• 組み換えタンパク質
• 細胞・遺伝子治療
• 抗体薬物複合体（ADC）
• 治療用酵素
• 世界のバイオ医薬品CMOおよびCRO市場バイオシミラーの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• バイオシミラーモノクローナル抗体
• バイオシミラーインスリン
• バイオシミラー成長ホルモン
• バイオシミラーエリスロポエチン
• バイオシミラー顆粒球コロニー刺激因子（G-CSF）

第7章 地域別・国別分析

• 世界のバイオ医薬品CMOおよびCRO市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のバイオ医薬品CMOおよびCRO市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオ医薬品CMOおよびCRO市場：競合情勢
• バイオ医薬品CMOおよびCRO市場：企業プロファイル
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis
  • Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
  • Syneos Health Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Catalent Inc.
• Charles River Laboratories International Inc.
• Parexel International（MA）Corporation
• Samsung Biologics Co. Ltd.
• CELLTRION INC.
• Medpace Holdings Inc.
• Fujifilm Diosynth Biotechnologies UK Limited
• Almac Group
• Pharmaron Beijing Co. Ltd.
• Worldwide Clinical Trials
• KBI Biopharma
• Inotiv Inc.
• Caidya
• Rentschler Biopharma SE
• Celerion Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• バイオ医薬品CMOおよびCRO市場2029：新たな機会を提供する国
• バイオ医薬品CMOおよびCRO市場2029：新たな機会を提供するセグメント
• バイオ医薬品CMOおよびCRO市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Biopharmaceutical contract manufacturing organizations (CMOs) and contract research organizations (CROs) are companies that offer outsourced services to biopharmaceutical companies. CMOs are responsible for the manufacturing and production of drugs, while CROs focus on research and development activities, including clinical trials and regulatory support. Both types of organizations help biopharmaceutical companies lower costs and accelerate the drug development process.

The primary products offered by biopharmaceutical CMOs and CROs include biologics and biosimilars. Biologics are complex medicines derived from living organisms, used to treat a range of diseases such as cancer, autoimmune disorders, and infectious diseases. These organizations provide various services, including contract manufacturing and contract research, with different methods of production, encompassing both mammalian and non-mammalian sources.

The biopharmaceutical CMO and CRO market research report is one of a series of new reports from The Business Research Company that provides biopharmaceutical CMO and CRO market statistics, including the biopharmaceutical CMO and CRO industry global market size, regional shares, competitors with the biopharmaceutical CMO and CRO market share, detailed biopharmaceutical CMO and CRO market segments, market trends, and opportunities, and any further data you may need to thrive in the biopharmaceutical CMO and CRO industry. These biopharmaceutical CMO and CRO market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biopharmaceutical cmo and cro market size has grown strongly in recent years. It will grow from $33.33 $ billion in 2024 to $35.6 $ billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing investment in biopharmaceutical R&D, growing demand for innovative therapies, expanding biologics pipeline, high growth in biopharmaceutical, and development in outsourcing strategies by pharmaceutical companies.

The biopharmaceutical cmo and cro market size is expected to see strong growth in the next few years. It will grow to $45.89 $ billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to rising outsourcing of drug development and manufacturing, increasing focus on cost-effective production methods, expanding therapeutic areas and drug pipelines, increasing demand for personalized medicine, and higher investments in biotechnology startups. Major trends in the forecast period include rising adoption of automated and high-throughput technologies, increasing use of advanced analytics and AI in drug development, growth in demand for cell and gene therapies, increasing integration of digital technologies in clinical trials, and rise in outsourcing of complex biopharmaceutical processes.

The biopharmaceutical CMO (Contract Manufacturing Organization) and CRO (Contract Research Organization) market is expected to grow due to increasing investments in research and development. These investments are driven by factors such as the need for innovation, competitive pressures, evolving market demands, and government incentives. Enhanced R&D funding allows CMOs and CROs to develop improved manufacturing techniques and research processes, boosting their capabilities and efficiency. This focus on innovation attracts and retains clients by offering advanced solutions while ensuring regulatory compliance. For example, Eurostat reported in December 2023 that EU expenditure on R&D rose to €352 billion ($384.42 billion) in 2022, a 6.34% increase from €331 billion ($361.48 billion) in the previous year. This growing R&D investment is fueling the expansion of the biopharmaceutical CMO and CRO market.

Leading companies in the biopharmaceutical CMO and CRO market are forming strategic partnerships to improve services, boost efficiencies, and speed up drug development for biopharmaceutical firms. Strategic partnerships involve companies combining their strengths and resources to achieve shared goals and mutual success. For example, in June 2024, Abzena plc, a UK-based biopharmaceutical company, entered into a partnership with Argonaut Manufacturing Services Inc., a US-based contract manufacturing organization (CMO), to offer integrated drug development and manufacturing solutions. This collaboration aims to deliver faster, end-to-end drug development and manufacturing processes, enhancing efficiency, lowering costs, and streamlining biopharmaceutical production for their clients.

In June 2024, Great Point Partners, a US-based investment firm, acquired Lyocontract GmbH for an undisclosed amount. This acquisition enables Great Point Partners to enhance Lyocontract's contract manufacturing capabilities, including aseptic liquid filling, freeze-drying, and injectable medicine packaging. Lyocontract GmbH, based in Germany, is a CDMO specializing in drug product contract development and manufacturing.

Major companies operating in the biopharmaceutical cmo and cro market are Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, Eurofins Scientific SE, Lonza Group AG, Syneos Health Inc., Catalent Inc., Charles River Laboratories International Inc., Parexel International (MA) Corporation, Samsung Biologics Co. Ltd., CELLTRION INC., Medpace Holdings Inc., Fujifilm Diosynth Biotechnologies UK Limited, Almac Group, Pharmaron Beijing Co. Ltd., Worldwide Clinical Trials, KBI Biopharma, Inotiv Inc., Caidya, Rentschler Biopharma SE, Celerion Inc., TFS HEALTHCARE LIMITED

North America was the largest region in the biopharmaceutical CMO and CRO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo and cro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biopharmaceutical cmo and cro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biopharmaceutical CMO and CRO market includes revenues earned by entities by providing services such as formulation development, quality control and assurance, clinical trial management, data management, and analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biopharmaceutical CMO And CRO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biopharmaceutical cmo and cro market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biopharmaceutical cmo and cro ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biopharmaceutical cmo and cro market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Biologics; Biosimilars
• 2) By Service Type: Contract Manufacturing; Contract Research
• 3) By Source: Mammalian; Non-Mammalian
• Subsegments:
• 1) By Biologics: Monoclonal Antibodies (mAbs); Vaccines; Recombinant Proteins; Cell and Gene Therapies; Antibody-Drug Conjugates (ADCs); Therapeutic Enzymes
• 2) By Biosimilars: Biosimilar Monoclonal Antibodies; Biosimilar Insulins; Biosimilar Growth Hormones; Biosimilar Erythropoietins; Biosimilar Granulocyte Colony-Stimulating Factors (G-CSFs)
• Companies Mentioned: Thermo Fisher Scientific Inc.; Boehringer Ingelheim International GmbH; Eurofins Scientific SE; Lonza Group AG; Syneos Health Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biopharmaceutical CMO And CRO Market Characteristics

3. Biopharmaceutical CMO And CRO Market Trends And Strategies

4. Biopharmaceutical CMO And CRO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Biopharmaceutical CMO And CRO Growth Analysis And Strategic Analysis Framework

• 5.1. Global Biopharmaceutical CMO And CRO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Biopharmaceutical CMO And CRO Market Growth Rate Analysis
• 5.4. Global Biopharmaceutical CMO And CRO Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Biopharmaceutical CMO And CRO Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Biopharmaceutical CMO And CRO Total Addressable Market (TAM)

6. Biopharmaceutical CMO And CRO Market Segmentation

• 6.1. Global Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologics
• Biosimilars
• 6.2. Global Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Contract Manufacturing
• Contract Research
• 6.3. Global Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mammalian
• Non-Mammalian
• 6.4. Global Biopharmaceutical CMO And CRO Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies (mAbs)
• Vaccines
• Recombinant Proteins
• Cell and Gene Therapies
• Antibody-Drug Conjugates (ADCs)
• Therapeutic Enzymes
• 6.5. Global Biopharmaceutical CMO And CRO Market, Sub-Segmentation Of Biosimilars, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biosimilar Monoclonal Antibodies
• Biosimilar Insulins
• Biosimilar Growth Hormones
• Biosimilar Erythropoietins
• Biosimilar Granulocyte Colony-Stimulating Factors (G-CSFs)

7. Biopharmaceutical CMO And CRO Market Regional And Country Analysis

• 7.1. Global Biopharmaceutical CMO And CRO Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Biopharmaceutical CMO And CRO Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biopharmaceutical CMO And CRO Market

• 8.1. Asia-Pacific Biopharmaceutical CMO And CRO Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biopharmaceutical CMO And CRO Market

• 9.1. China Biopharmaceutical CMO And CRO Market Overview
• 9.2. China Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biopharmaceutical CMO And CRO Market

• 10.1. India Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biopharmaceutical CMO And CRO Market

• 11.1. Japan Biopharmaceutical CMO And CRO Market Overview
• 11.2. Japan Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biopharmaceutical CMO And CRO Market

• 12.1. Australia Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biopharmaceutical CMO And CRO Market

• 13.1. Indonesia Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biopharmaceutical CMO And CRO Market

• 14.1. South Korea Biopharmaceutical CMO And CRO Market Overview
• 14.2. South Korea Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biopharmaceutical CMO And CRO Market

• 15.1. Western Europe Biopharmaceutical CMO And CRO Market Overview
• 15.2. Western Europe Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biopharmaceutical CMO And CRO Market

• 16.1. UK Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biopharmaceutical CMO And CRO Market

• 17.1. Germany Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biopharmaceutical CMO And CRO Market

• 18.1. France Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biopharmaceutical CMO And CRO Market

• 19.1. Italy Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biopharmaceutical CMO And CRO Market

• 20.1. Spain Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biopharmaceutical CMO And CRO Market

• 21.1. Eastern Europe Biopharmaceutical CMO And CRO Market Overview
• 21.2. Eastern Europe Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biopharmaceutical CMO And CRO Market

• 22.1. Russia Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biopharmaceutical CMO And CRO Market

• 23.1. North America Biopharmaceutical CMO And CRO Market Overview
• 23.2. North America Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biopharmaceutical CMO And CRO Market

• 24.1. USA Biopharmaceutical CMO And CRO Market Overview
• 24.2. USA Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biopharmaceutical CMO And CRO Market

• 25.1. Canada Biopharmaceutical CMO And CRO Market Overview
• 25.2. Canada Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biopharmaceutical CMO And CRO Market

• 26.1. South America Biopharmaceutical CMO And CRO Market Overview
• 26.2. South America Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biopharmaceutical CMO And CRO Market

• 27.1. Brazil Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biopharmaceutical CMO And CRO Market

• 28.1. Middle East Biopharmaceutical CMO And CRO Market Overview
• 28.2. Middle East Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biopharmaceutical CMO And CRO Market

• 29.1. Africa Biopharmaceutical CMO And CRO Market Overview
• 29.2. Africa Biopharmaceutical CMO And CRO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Biopharmaceutical CMO And CRO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Biopharmaceutical CMO And CRO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biopharmaceutical CMO And CRO Market Competitive Landscape And Company Profiles

• 30.1. Biopharmaceutical CMO And CRO Market Competitive Landscape
• 30.2. Biopharmaceutical CMO And CRO Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Syneos Health Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Biopharmaceutical CMO And CRO Market Other Major And Innovative Companies

• 31.1. Catalent Inc.
• 31.2. Charles River Laboratories International Inc.
• 31.3. Parexel International (MA) Corporation
• 31.4. Samsung Biologics Co. Ltd.
• 31.5. CELLTRION INC.
• 31.6. Medpace Holdings Inc.
• 31.7. Fujifilm Diosynth Biotechnologies UK Limited
• 31.8. Almac Group
• 31.9. Pharmaron Beijing Co. Ltd.
• 31.10. Worldwide Clinical Trials
• 31.11. KBI Biopharma
• 31.12. Inotiv Inc.
• 31.13. Caidya
• 31.14. Rentschler Biopharma SE
• 31.15. Celerion Inc.

32. Global Biopharmaceutical CMO And CRO Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biopharmaceutical CMO And CRO Market

34. Recent Developments In The Biopharmaceutical CMO And CRO Market

35. Biopharmaceutical CMO And CRO Market High Potential Countries, Segments and Strategies

• 35.1 Biopharmaceutical CMO And CRO Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Biopharmaceutical CMO And CRO Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Biopharmaceutical CMO And CRO Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer